Nkgen Biotech, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OTC.Pink
SCHEDULE 13D: Major Investor Group Boosts Stake in NKGen Biotech to 47.2% Through New $2.5 Million Private Placement
CFIC-2015 NV Family Investments, LLC and its principals, Andrew and Peggy Cherng, have significantly increased their beneficial ownership in NKGen Biotech, Inc. to 47.2% through a recent $2.5 million private placement and associated warrants, signaling a strong investment interest and intent to monitor corporate governance.
OTC.Pink
SCHEDULE 13D: NKGen Biotech CEO Paul Y. Song Boosts Stake to 54.3% Through $2.65 Million Private Placement
NKGen Biotech, Inc. CEO Paul Y. Song has significantly increased his beneficial ownership to 54.3% of the company's common stock through a $2.65 million private placement, acquiring shares and warrants.